CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2433-2435

  Heinemann, V ^a   Schermuly, M M ^b   Stieber, P ^b   Schulz, L ^b   Jungst D ^b   Wilkowski, R ^b   Schalhorn, A ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

CA19 9; Cisplatin; Gemcitabin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CA 19-9 ANTIGEN; CISPLATIN; GEMCITABINE; PYRIMIDINE ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; HUMAN; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032780681     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Kelly DM, Benjamin IS: Pancreatic carcinoma. Ann Oncol 6: 19-28, 1995.
2. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ: A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627-32, 1996.
3. Warshaw AL, Del Castillo F: Pancreatic Carcinoma. N Engl J Med 326: 455-465, 1992.
4. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Starniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff D: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350-355, 1990.
6. Heinemann V, Wilke H, Possinger K, Mergenthaler K, Clemens M, König H J, Illiger H J, Lackhoff A, Blatter J, Schalhorn A, Fink U: Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic carcinoma. Eur J Cancer 33 (Suppl 8): S274, 1240, 1997.
7. Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ: A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Caner 73: 1260-1264, 1996.
8. Rothman H, Cantrell J E, Lokich J, Difino S, Harvey J, Ahlgren J, Fryer J: Continuous infusion of 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer 68: 264-268, 1991.
9. Rougier P, Zarba JJ, Ducreux M, Basile M, Pignon JP, Mahjoubi M, Benahmed M, Droz JP, Cvitkovic E, Armand JP: Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4: 333-336, 1993.
10. Wils JA, Kok T, Wagener DJ Th, Selleslags J, Duez N: Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A: 203-204, 1993.
11. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6: 462-468, 1988.
12. Gattani AM, Mandeli J, Bruckner HW: Tumor markers in patients with pancreatic carcinoma. Cancer 78: 57-62, 1996.
13. Lundin J, Roberts PJ, Kuusela P, Haglund C: The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer Br J Cancer 69: 515-519, 1994.
14. Willett CG, Daly WJ, Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352, 1996.
15. Yamaue H, Taniumura H, Aoki Y, Tsunoda T, Iwahashi M, Tani M, Tamai M, Noguchi K, Kashiwagi H, Sasaki M, Yamada R: Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer. J Surg Oncol 49: 10-15, 1992.